Crises in sickle cell disease

Chest

Volumn 149, Issue 4, 2016, Pages 1082-1093

  Novelli, Enrico M ^a,b   Gladwin, Mark T ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute chest syndrome; Red blood cells; Sickle cell disease; Transfusion

Indexed keywords

CEPHALOSPORIN; MACROLIDE; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT;

ACUTE CHEST SYNDROME; ANEMIA; APLASTIC CRISIS; ARTICLE; BLOOD TRANSFUSION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC LUNG DISEASE; DISEASE PREDISPOSITION; EXCHANGE BLOOD TRANSFUSION; HUMAN; IMMUNE DYSREGULATION; INTRAHEPATIC CHOLESTASIS; MORBIDITY; MORTALITY RATE; MULTIPLE ORGAN FAILURE; NONHUMAN; OXYGEN THERAPY; PATHOPHYSIOLOGY; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; SEPSIS; SICKLE CELL ANEMIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE; ANALGESIA; ANEMIA, APLASTIC; ANEMIA, SICKLE CELL; BLOOD GROUP TYPING; COMPLICATION; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; PAIN; PROCEDURES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; STROKE;

ACUTE CHEST SYNDROME; ANEMIA, APLASTIC; ANEMIA, SICKLE CELL; ANTI-BACTERIAL AGENTS; BLOOD GROUPING AND CROSSMATCHING; DISEASE PROGRESSION; ERYTHROCYTE TRANSFUSION; EXCHANGE TRANSFUSION, WHOLE BLOOD; HUMANS; MULTIPLE ORGAN FAILURE; OXYGEN INHALATION THERAPY; PAIN; PAIN MANAGEMENT; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PURPURA, THROMBOTIC THROMBOCYTOPENIC; STROKE;

EID: 84964452501     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2015.12.016     Document Type: Review

References (122)

1. Akinola NO, Stevens SM, Franklin IM, et al. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol. 1992;45(10):902-906.
2. Akinola NO, Stevens SM, Franklin IM, et al. Rheological changes in the prodromal and established phases of sickle cell vaso-occlusive crisis. Br J Haematol. 1992;81(4):598-602.
3. Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med. 2000;342(25):1910-1912.
4. Hebbel RP, Boogaerts MA, Eaton JW, et al. Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity. N Engl J Med. 1980;302(18):992-995.
5. Hebbel RP, Boogaerts MA, Koresawa S, et al. Erythrocyte adherence to endothelium as a determinant of vasocclusive severity in sickle cell disease. Trans Assoc Am Physicians. 1980;93:94-99.
6. Hebbel RP, Yamada O, Moldow CF, et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980;65(1):154-160.
7. Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A. 1989;86(9):3356-3360.
8. Kaul DK, Fabry ME, Nagel RL. Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. Blood. 1986;68(5): 1162-1166.
9. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106(3):411-420.
10. Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008;93(1):20-26.
11. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003;101(10):3953-3959.
12. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 1996;81(1):96-98.
13. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106(3):337-338.
14. Lester LA, Sodt PC, Hutcheon N, et al. Cardiac abnormalities in children with sickle cell anemia. Chest. 1990;98(5):1169-1174.
15. Meloni A, Detterich J, Berdoukas V, et al. Comparison of biventricular dimensions and function between pediatric sickle-cell disease and thalassemia major patients without cardiac iron. Am J Hematol. 2013;88(3):213-218.
16. Fitzhugh CD, Lauder N, Jonassaint JC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol. 2010;85(1):36-40.
17. Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol. 2012;59(13):1123-1133.
18. Thompson J, Reid M, Hambleton I, et al. Albuminuria and renal function in homozygous sickle cell disease: observations from a cohort study. Arch Intern Med. 2007;167(7):701-708.
19. Saraf SL, Zhang X, Kanias T, et al. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol. 2014;164(5):729-739.
20. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
21. Howard J, Hart N, Roberts-Harewood M, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol. 2015;169(4):492-505.
22. Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189(6):727-740.
23. Vichinsky EP, Neumayr LD, Earles AN, et al; and the National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865.
24. Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course: Cooperative Study of Sickle Cell Disease. Blood. 1997;89(5):1787-1792.
25. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
26. Knight-Madden JM, Forrester TS, Lewis NA, et al. The impact of recurrent acute chest syndrome on the lung function of young adults with sickle cell disease. Lung. 2010;188(6):499-504.
27. Charache S, Scott JC, Charache P. "Acute chest syndrome" in adults with sickle cell anemia: microbiology, treatment, and prevention. Arch Intern Med. 1979;139(1):67-69.
28. Bope ET, Kellerman RD. Conn's Current Therapy 2016. Philadelphia, PA: Elsevier; 2016.
29. Mekontso Dessap A, Deux JF, Habibi A, et al. Lung imaging during acute chest syndrome in sickle cell disease: computed tomography patterns and diagnostic accuracy of bedside chest radiograph. Thorax. 2014;69(2):144-151.
30. Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood. 1994;83(11):3107-3112.
31. Adisa OA, Hu Y, Ghosh S, et al. Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease. Br J Haematol. 2013;162(5):702-705.
32. Stankovic Stojanovic K, Steichen O, Lefevre G, et al. High lactate dehydrogenase levels at admission for painful vaso-occlusive crisis is associated with severe outcome in adult SCD patients. Clin Biochem. 2012;45(18):1578-1582.
33. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11):4809-4820.
34. Rucknagel DL. The role of rib infarcts in the acute chest syndrome of sickle cell diseases. Pediatr Pathol Mol Med. 2001;20(2):137-154.
35. Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333(11):699-703.
36. Novelli EM, Huynh C, Gladwin MT, et al. Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost. 2012;10(5):760-766.
37. Mekontso Dessap A, Deux JF, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2011;184(9):1022-1029.
38. Hagger D, Wolff S, Owen J, et al. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis. 1995;6(2):93-99.
39. Tomer A, Harker LA, Kasey S, et al. Thrombogenesis in sickle cell disease. J Lab Clin Med. 2001;137(6):398-407.
40. Wang A, Liu F, Dong N, et al. Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro. Thromb Res. 2010;126(4):e260-e265.
41. Strouse JJ, Reller ME, Bundy DG, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood. 2010;116(18):3431-3434.
42. Emre U, Miller ST, Gutierez M, et al. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr. 1995;127(6):901-904.
43. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
44. Mekontso Dessap A, Leon R, Habibi A, et al. Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2008;177(6):646-653.
45. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
46. Charache S, Terrin ML, Moore RD, et al; and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
47. Mallouh AA, Asha M. Beneficial effect of blood transfusion in children with sickle cell chest syndrome. Am J Dis Child. 1988;142(2):178-182.
48. Castro O. Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am. 1996;10(6): 1289-1303.
49. Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med. 1994;96(2):155-162.
50. Vlachaki E, Agapidou A, Neokleous N, et al. Thrombotic thrombocytopenic purpura or immune thrombocytopenia in a sickle cell/b+-thalassemia patient: a rare and challenging condition. Transfus Apher Sci. 2014;51(2):175-177.
51. Venkata Sasidhar M, Tripathy AK, Viswanathan K, et al. Thrombotic thrombocytopenic purpura and multiorgan system failure in a child with sickle cell-hemoglobin C disease. Clin Pediatr (Phila). 2010;49(10):992-996.
52. Shelat SG. Thrombotic thrombocytopenic purpura and sickle cell crisis. Clin Appl Thromb Hemost. 2010;16(2):224-227.
53. Lee HE, Marder VJ, Logan LJ, et al. Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease. Ann Hematol. 2003;82(11):702-704.
54. Bolanos-Meade J, Keung YK, Lopez-Arvizu C, et al. Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis. Ann Hematol. 1999;78(12):558-559.
55. Chinowsky MS. Thrombotic thrombocytopenic purpura associated with sickle cell-hemoglobin C disease. South Med J. 1994;87(11): 1168-1171.
56. Chen J, Hobbs WE, Le J, et al. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011;117(13):3680-3683.
57. Novelli EM, Kato GJ, Hildesheim ME, et al. Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica. 2013;98(11):e132-e134.
58. Schnog JJ, Hovinga JA, Krieg S, et al. ADAMTS13 activity in sickle cell disease. Am J Hematol. 2006;81(7):492-498.
59. Boyd JH, Macklin EA, Strunk RC, et al. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;108(9):2923-2927.
60. Knight-Madden JM, Forrester TS, Lewis NA, et al. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax. 2005;60(3):206-210.
61. Field JJ, Stocks J, Kirkham FJ, et al. Airway hyperresponsiveness in children with sickle cell anemia. Chest. 2011;139(3):563-568.
62. Field JJ, Glassberg J, Gilmore A, et al. Longitudinal analysis of pulmonary function in adults with sickle cell disease. Am J Hematol. 2008;83(7):574-576.
63. Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 1998;92(9):3082-3089.
64. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994;330(11):733-737.
65. Fartoukh M, Lefort Y, Habibi A, et al. Early intermittent noninvasive ventilation for acute chest syndrome in adults with sickle cell disease: a pilot study. Intensive Care Med. 2010;36(18): 1355-1362.
66. Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood. 1986;67(5):1411-1417.
67. Tsitsikas DA, Gallinella G, Patel S, et al. Bone marrow necrosis and fat embolism syndrome in sickle cell disease: increased susceptibility of patients with non-SS genotypes and a possible association with human parvovirus B19 infection. Blood Rev. 2014;28(1):23-30.
68. Naymagon L, Pendurti G, Billett HH. Acute splenic sequestration crisis in adult sickle cell disease: a report of 16 cases. Hemoglobin. 2015;39(6):375-379.
69. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease: the Cooperative Study of Sickle Cell Disease. Blood. 1990;76(7):1431-1437.
70. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):1617-1621.
71. Alarif L, Castro O, Ofosu M, et al. HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clin Immunol Immunopathol. 1986;38(2):178-183.
72. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood. 2008;112(6):2546-2553.
73. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062-1071.
74. King KE, Shirey RS, Lankiewicz MW, et al. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion. 1997;37(4):376-381.
75. Talano JA, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003;111(6 Pt 1):e661-e665.
76. Win N, Doughty H, Telfer P, et al. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion. 2001;41(3):323-328.
77. Win N, New H, Lee E, et al. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion. 2008;48(6):1231-1238.
78. Sirchia G, Morelati F, Rebulla P. The sickle cell hemolytic transfusion reaction syndrome. Transfusion. 1997;37(10):1098-1099.
79. Win N, Yeghen T, Needs M, et al. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. Hematology. 2004;9(5-6):433-436.
80. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
81. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
82. Belizna C, Loufrani L, Ghali A, et al. Arterial stiffness and stroke in sickle cell disease. Stroke. 2012;43(4):1129-1130.
83. Merkel KH, Ginsberg PL, Parker JC Jr, et al. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke. 1978;9(1):45-52.
84. Kugler S, Anderson B, Cross D, et al. Abnormal cranial magnetic resonance imaging scans in sickle-cell disease. Neurological correlates and clinical implications. Arch Neurol. 1993;50(6):629-635.
85. Strouse JJ, Cox CS, Melhem ER, et al. Inverse correlation between cerebral blood flow measured by continuous arterial spin-labeling (CASL) MRI and neurocognitive function in children with sickle cell anemia (SCA). Blood. 2006;108(1):379-381.
86. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2012;119(16):3684-3690.
87. Kirkham FJ, DeBaun MR. Stroke in children with sickle cell disease. Curr Treat Options Neurol. 2004;6(5):357-375.
88. Chien S, Kaperonis AA, King RG, et al. Rheology of sickle cells and its role in microcirculatory dynamics. Prog Clin Biol Res. 1987;240: 151-165.
89. Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels: implications for transfusion. Transfusion. 1987;27(3):228-233.
90. Alkan O, Kizilkilic E, Kizilkilic O, et al. Cranial involvement in sickle cell disease. Eur J Radiol. 2010;76(2):151-156.
91. Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 2002;99(9):3144-3150.
92. Drew JM, Scott JA, Chua GT. General case of the day: moyamoya syndrome in a child with sickle cell disease. Radiographics. 1993;13(2):483-484.
93. Geevasinga N, Cole C, Herkes GK, et al. Sickle cell disease and posterior reversible leukoencephalopathy. J Clin Neurosci. 2014;21(8):1329-1332.
94. Henderson JN, Noetzel MJ, McKinstry RC, et al. Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease. Blood. 2003;101(2):415-419.
95. Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy. Hepatology. 2001;33(5):1021-1028.
96. Lee ES, Chu PC. Reverse sequestration in a case of sickle crisis. Postgrad Med J. 1996;72(850):487-488.
97. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314(25):1593-1599.
98. Baskin MN, Goh XL, Heeney MM, et al. Bacteremia risk and outpatient management of febrile patients with sickle cell disease. Pediatrics. 2013;131(6):1035-1041.
99. Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010; 115(17):3447-3452.
100. Alkindi S, Matwani S, Al-Maawali A, et al. Complications of PORTA-CATH in patients with sickle cell disease. J Infect Public Health. 2012;5(1):57-62.
101. Chulamokha L, Scholand SJ, Riggio JM, et al. Bloodstream infections in hospitalized adults with sickle cell disease: a retrospective analysis. Am J Hematol. 2006;81(10):723-728.
102. Zarrouk V, Habibi A, Zahar JR, et al. Bloodstream infection in adults with sickle cell disease: association with venous catheters, Staphylococcus aureus, and bone-joint infections. Medicine (Baltimore). 2006;85(1):43-48.
103. Wagner SC, Eschelman DJ, Gonsalves CF, et al. Infectious complications of implantable venous access devices in patients with sickle cell disease. J Vasc Interv Radiol. 2004;15(4):375-378.
104. Green NS. Yersinia infections in patients with homozygous b-thalassemia associated with iron overload and its treatment. Pediatr Hematol Oncol. 1992;9(3):247-254.
105. Abcarian PW, Demas BE. Systemic Yersinia enterocolitica infection associated with iron overload and deferoxamine therapy. AJR Am J Roentgenol. 1991;157(4):773-775.
106. Mazzoleni G, deSa D, Gately J, et al. Yersinia enterocolitica infection with ileal perforation associated with iron overload and deferoxamine therapy. Dig Dis Sci. 1991;36(8):1154-1160.
107. Gallant T, Freedman MH, Vellend H, et al. Yersinia sepsis in patients with iron overload treated with deferoxamine. N Engl J Med. 1986;314(25):1643.
108. Robins-Browne RM, Prpic JK. Desferrioxamine and systemic yersiniosis. Lancet. 1983;2(8363):1372.
109. van Eijk LT, Heemskerk S, van der Pluijm RW, et al. The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: a randomized trial. Haematologica. 2014;99(3):579-587.
110. McAuley CF, Webb C, Makani J, et al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood. 2010;116(10):1663-1668.
111. Makani J, Komba AN, Cox SE, et al. Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood. 2010;115(2):215-220.
112. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512-S521.
113. Chang J, Shi PA, Chiang EY, et al. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood. 2008;111(2):915-923.
114. Turhan A, Jenab P, Bruhns P, et al. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood. 2004;103(6):2397-2400.
115. Field JJ, Lin G, Okam MM, et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood. 2013;121(17):3329-3334.
116. Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vasoocclusive events and decreased opioid use. Blood. 2015;125(17): 2656-2664.
117. Maitre B, Djibre M, Katsahian S, et al. Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study. Intensive Care Med. 2015;41(12):2121-2129.
118. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305(9):893-902.
119. Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebocontrolled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98(9):1375-1382.
120. Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118(4):855-864.
121. Mack AK, McGowan VR II, Tremonti CK, et al. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. Br J Haematol. 2008;142(6):971-978.
122. Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8): 1276-1284.